# A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

> **NCT03400332** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 281 (actual)

## Conditions studied

- Cancer
- Melanoma

## Interventions

- **DRUG:** BMS-986253
- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Ipilimumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03400332
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-12
- **Primary completion:** 2024-04-26
- **Final completion:** 2025-12-04
- **Target enrollment:** 281 (ACTUAL)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03400332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03400332, "A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03400332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*